-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
FibroGen (NASDAQ:FGEN) Given New $14.00 Price Target at Cowen
FibroGen (NASDAQ:FGEN) Given New $14.00 Price Target at Cowen
FibroGen (NASDAQ:FGEN – Get Rating) had its price target raised by Cowen to $14.00 in a research report report published on Monday morning, Stock Target Advisor reports.
Several other analysts have also recently commented on the stock. StockNews.com cut shares of FibroGen from a buy rating to a hold rating in a report on Wednesday, August 10th. The Goldman Sachs Group reduced their target price on shares of FibroGen from $9.00 to $8.00 and set a sell rating for the company in a research note on Tuesday, May 24th.
Get FibroGen alerts:FibroGen Price Performance
Shares of FGEN opened at $14.59 on Monday. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -6.16 and a beta of 0.87. The company has a 50-day moving average of $11.91 and a two-hundred day moving average of $11.98. FibroGen has a one year low of $7.81 and a one year high of $16.91.
FibroGen (NASDAQ:FGEN – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.16. The business had revenue of $29.81 million during the quarter, compared to analysts' expectations of $36.15 million. FibroGen had a negative net margin of 83.64% and a negative return on equity of 100.51%. The firm's quarterly revenue was up 22.3% compared to the same quarter last year. During the same period last year, the company posted ($1.45) earnings per share. Analysts anticipate that FibroGen will post -3 earnings per share for the current year.Institutional Trading of FibroGen
A number of institutional investors have recently added to or reduced their stakes in FGEN. Point72 Asset Management L.P. lifted its stake in FibroGen by 235.9% in the fourth quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company's stock valued at $52,630,000 after acquiring an additional 2,621,494 shares during the last quarter. Soleus Capital Management L.P. bought a new position in shares of FibroGen in the fourth quarter valued at approximately $21,862,000. Federated Hermes Inc. raised its position in shares of FibroGen by 84.1% in the first quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company's stock valued at $28,799,000 after purchasing an additional 1,094,403 shares during the period. First Trust Advisors LP raised its position in shares of FibroGen by 24.8% in the fourth quarter. First Trust Advisors LP now owns 5,317,613 shares of the biopharmaceutical company's stock valued at $74,978,000 after purchasing an additional 1,055,536 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in FibroGen by 333.0% during the second quarter. Assenagon Asset Management S.A. now owns 972,901 shares of the biopharmaceutical company's stock worth $10,274,000 after acquiring an additional 748,230 shares during the period. 77.35% of the stock is currently owned by institutional investors and hedge funds.
FibroGen Company Profile
(Get Rating)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
See Also
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- 3 Blowout Earnings Reports That Could Mark Turning Points
- Will CrowdStrike Extend Its Streak Of Topping Earnings Views?
- Skyworks Solutions Is Worth A Look At These Prices
- 3 Stocks Set to Lead the Nasdaq Bull Market
- MarketBeat Podcast: ESG – Profitably Invest Your Values
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
FibroGen (NASDAQ:FGEN – Get Rating) had its price target raised by Cowen to $14.00 in a research report report published on Monday morning, Stock Target Advisor reports.
據Stock Target Advisor報道,考恩在週一上午發佈的一份研究報告中將FibroGen(納斯達克:FDEN-GET評級)的目標價上調至14.00美元。
Several other analysts have also recently commented on the stock. StockNews.com cut shares of FibroGen from a buy rating to a hold rating in a report on Wednesday, August 10th. The Goldman Sachs Group reduced their target price on shares of FibroGen from $9.00 to $8.00 and set a sell rating for the company in a research note on Tuesday, May 24th.
其他幾位分析師最近也對該股發表了評論。在8月10日星期三的一份報告中,StockNews.com將FibroGen的股票評級從買入下調至持有。5月24日,高盛夫婦將FibroGen的股票目標價從9.00美元下調至8.00美元,並在週二的一份研究報告中為該公司設定了賣出評級。
FibroGen Price Performance
FibroGen性價比
Shares of FGEN opened at $14.59 on Monday. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -6.16 and a beta of 0.87. The company has a 50-day moving average of $11.91 and a two-hundred day moving average of $11.98. FibroGen has a one year low of $7.81 and a one year high of $16.91.
週一,fgen的股價開盤報14.59美元。該股市值為13.7億美元,市盈率為-6.16倍,貝塔係數為0.87。該公司的50日移動均線切入位在11.91美元,200日移動均線切入位在11.98美元。FibroGen的一年低點為7.81美元,一年高位為16.91美元。
Institutional Trading of FibroGen
FibroGen的機構交易
A number of institutional investors have recently added to or reduced their stakes in FGEN. Point72 Asset Management L.P. lifted its stake in FibroGen by 235.9% in the fourth quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company's stock valued at $52,630,000 after acquiring an additional 2,621,494 shares during the last quarter. Soleus Capital Management L.P. bought a new position in shares of FibroGen in the fourth quarter valued at approximately $21,862,000. Federated Hermes Inc. raised its position in shares of FibroGen by 84.1% in the first quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company's stock valued at $28,799,000 after purchasing an additional 1,094,403 shares during the period. First Trust Advisors LP raised its position in shares of FibroGen by 24.8% in the fourth quarter. First Trust Advisors LP now owns 5,317,613 shares of the biopharmaceutical company's stock valued at $74,978,000 after purchasing an additional 1,055,536 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in FibroGen by 333.0% during the second quarter. Assenagon Asset Management S.A. now owns 972,901 shares of the biopharmaceutical company's stock worth $10,274,000 after acquiring an additional 748,230 shares during the period. 77.35% of the stock is currently owned by institutional investors and hedge funds.
一些機構投資者最近增持或減持了fgen的股份。Point72 Asset Management L.P.在第四季度將其在FibroGen的持股比例提高了235.9%。Point72 Asset Management L.P.在上個季度額外收購了2,621,494股後,現在擁有這家生物製藥公司3732,594股股票,價值52,630,000美元。Soleus Capital Management L.P.在第四季度購買了FibroGen的新頭寸,價值約21,862,000美元。聯合愛馬仕公司在第一季度將其在FibroGen的股票持倉量提高了84.1%。聯合愛馬仕公司目前持有這家生物製藥公司2,395,883股股票,價值28,799,000美元,在此期間又購買了1,094,403股。First Trust Advisors LP在第四季度將其在FibroGen股票的頭寸提高了24.8%。First Trust Advisors LP現在擁有這家生物製藥公司5,317,613股股票,價值74,978,000美元,在此期間又購買了1,055,536股。最後,Assenagon Asset Management S.A.在第二季度將其在FibroGen的頭寸增加了333.0%。Assenagon Asset Management S.A.在此期間額外收購了748,230股票,現在擁有972,901股這家生物製藥公司的股票,價值10,274,000美元。77.35%的股票目前由機構投資者和對衝基金持有。
FibroGen Company Profile
FibroGen公司簡介
(Get Rating)
(獲取評級)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen,Inc.是一家生物製藥公司,發現、開發和商業化治療嚴重未得到滿足的醫療需求的療法。該公司正在開發一種口服低氧誘導因子Pro羥基酶小分子抑制劑roxadustat,該藥已在美國、歐洲、中國和日本完成了治療慢性腎臟疾病貧血的第三階段臨牀開發,並在中國完成了治療與骨髓增生異常綜合徵相關的貧血的第二/第三階段臨牀開發。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- 3 Blowout Earnings Reports That Could Mark Turning Points
- Will CrowdStrike Extend Its Streak Of Topping Earnings Views?
- Skyworks Solutions Is Worth A Look At These Prices
- 3 Stocks Set to Lead the Nasdaq Bull Market
- MarketBeat Podcast: ESG – Profitably Invest Your Values
- 免費獲取StockNews.com關於FibroGen的研究報告(Fgen)
- 3份井噴式收益報告可能標誌着轉折點
- CrowdStrike是否會延續其盈利排行榜榜首的勢頭?
- Skyworks Solutions值得看看這些價格
- 3只股票將引領納斯達克牛市
- MarketBeat播客:ESG--有利可圖地投資你的價值
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對FibroGen和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧